

Joint Event

38th International Conference on

Advanced Pediatrics and Neonatology

29th Global Dentists and

Pediatric Dentistry Meeting

8th International Conference & Expo on

Euro Optometry and Vision Science

March 20-21, 2023

Rome, Italy

Gen Med 2023, Volume 11

Latest clinical evidence and experience on D.I.M.S. spectacle lenses

Pascal Blaser

Hoya Vision, Switzerland

In recent years, special-designed spectacle lenses, especially those based on the defocus theory, provided Eye Care Professionals (ECPs) worldwide with a safe and effective tool for myopia control among their young patients. When MiYOSMART spectacle lenses with Defocus Incorporated Multiple Segments (D.I.M.S.) Technology was launched in Europe a few years ago; it was backed with scientific evidence from a 2-year randomized clinical trial and clinical experience from ECPs from Asia. While ECPs in Europe embrace this new technology in their practice, evidence from a longer treatment time and experience from the non-Asian ethnicity populations will further build the confidence of ECPs in Europe and across the world in integrating D.I.M.S. Technology into their daily practice. We gathered publically available clinical evidence for D.I.M.S. spectacle lenses, which demonstrated a sustained effect of slowing down myopia progression for 6 years. The data also indicate that there is no rebound effect after switching to single-vision spectacle lenses. With regard to the role of ethnicity, more and more clinical experience indicates that D.I.M.S. spectacle lenses work well among European children. In this meeting, experience from several experts across Europe in the myopia management field will be shared based on the observation of hundreds of their own patients. Their data suggest that D.I.M.S. spectacle lenses offer a safe, simple and effective way of myopia control for European children. Some practical tips will also be shared.